Erin Burkhart
Vermogen: 811 971 $ op 31-05-2026
Vermogen: 811 971 $ op 31-05-2026
Erin E.
Burkhart is Chief Accounting Officer, Senior VP & Controller at Gilead Sciences, Inc. starting in 2025.
Former roles include Chief Accounting Officer & Group Vice President at BioMarin Pharmaceutical, Inc. from 2022 to 2025, and Associate VP-US Gross-to-Net Business Analysis at Eli Lilly & Co. from 2021 to 2022.
Education includes undergraduate studies at Butler University.
| Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
|---|---|---|---|---|
| 20-05-2025 | 14.173 ( 0,01% ) | 811 971 $ | 31-05-2026 |
| Bedrijven | Functie | Begin |
|---|---|---|
| GILEAD SCIENCES, INC. | Comptroller/Controller/Auditor | 22-09-2025 |
| Bedrijven | Functie | Einde |
|---|---|---|
| BIOMARIN PHARMACEUTICAL INC. | Comptroller/Controller/Auditor | 02-09-2025 |
| ELI LILLY AND COMPANY | Corporate Officer/Principal | 01-04-2022 |
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
| Bedrijven in privébezit | 4 |
|---|---|
Gilead Sciences, Inc.
Gilead Sciences, Inc. BiotechnologyHealth Technology Discovers, develops and commercializes therapeutic products and treatments for life threatening diseases | Health Technology |
Eli Lilly & Co.
Eli Lilly & Co. Pharmaceuticals: MajorHealth Technology Manufactures, wholesales and markets pharmaceutical products | Health Technology |
BioMarin Pharmaceutical, Inc.
BioMarin Pharmaceutical, Inc. BiotechnologyHealth Technology Discovers, develops and commercializes innovative pharmaceuticals for serious diseases & medical conditions | Health Technology |
Butler University
Butler University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Kies jouw editie
Alle financiële informatie op nationaal niveau